post image
In February this year the Spanish ministry of health (Ministerio de Sanidad) made the decision to ban the use of Quality-Adjusted Life Year’s (QALYs) in health decision making, describing this approach as too subjective ...

Is the QALY losing its value for use in health decision making?

post image
We came across this article recently which uses the great analogy of alien termite invasion and raygun’s to explain, in accessible terms, what’s gone awry with the US healthcare system and how they can fix ...

Fighting alien invasion and saving the US healthcare system

post image
I came across this primer from HBR on the impact of high deductible health plans (HDHPs).  We all know that in the US people pay for health insurance, and that in many cases it's necessary for patients to make ...

Is the US trading personal and system wide affordability of health care?

post image
We've been watching the Sovaldi® launch with interest for a while now.  Early reports have shown the product making significant inroads in the US, although there has been some indication that Medicaid is seeking to ...

Sovaldi® – a watershed moment in the UK too?

post image
One of the fun things that we do is run a public course on the 'Principles of Pharma Market Access in Europe', working as faculty of CELforPharma, to provide a helicopter view of the key healthcare systems.  At least one ...

Help! How are access decisions made for pharmaceuticals?

post image
Not money, but approaches. Following on from an earlier post by Nick, I saw this.  It's kind of important to be aware of for all the reasons that Nick mentioned in his earlier post.  So now payer organisations who in ...

US PBMs borrowing from Europe to manage costs

post image
Not something you would normally think about I guess. Having said that, I read this on PM live and thought it was a brilliant idea to help raise awareness about skin cancer. Ogilvy Brasil are working with Rio de ...

What do Tattoo Artists & Dermatologists
have in common?

post image
The US launch of Sovaldi® in late 2013 is proving to be a runaway success for Gilead.  However, this may just be the start of something.  We’ve been watching the situation unfold with a good degree of ...

Sovaldi®: a watershed moment in the US?

post image
We spend quite a bit of time talking to clients or potential clients about the biosimilar threat. (We've posted on the latest European experience here).  There are lots of questions about what this will mean for the branded ...

A biosimilar defense strategy from Roche?

post image
Yes, I did just write that title. Please bear with me while I make my case. Matthew McConaughey was famous for being a Hollywood heartthrob starring in a string of romantic comedies which were generally panned by critics ...

What can pharma learn from Matthew McConaughey?

post image
I had a great catch up yesterday with the inestimable John Wilson, planning guru and all-round legend in healthcare advertising.  We had a great time teasing our former colleague Mike about the challenges ahead but also ...

What can the next generation
of consultants teach us?

post image
I saw this article and it reminded me of discussions we've had in the office about NHS England's plans to make semi-anonymised patient level information available in the Care.data.  We talked about how what initially ...

Privacy: meta-data is not ‘don’t matter’ data